CHORUS Study
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Disease site
Ovary
Pubmed link
Publication month/year
May 2015
Study question
Is Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) non-inferior to Primary Debulking Surgery (PDS)
Type of study
Randomised controlled trial (RCT)
Interventions compared
NACT/IDS vs PDS
Experimental arm (Intervention)
PDS
Control arm
NACT/IDS (AUC5 or AUC6 Carboplatin plus Paclitaxel 175 mg/m2 every 3 weeks)
Primary outcome
Overall survival (OS)
Secondary outcome
- Progression Free Survival (RFS)
- QoL
Inclusion criteria
- Women with clinically stage 3 or 4 ovarian cancer
- Ca125/ CEA > 25
Exclusion criteria
Contraindication to PDS or NACT/IDS
Results
Conclusions
NACT/IDS is non-inferior to PDS in advanced ovarian cancer
Study limitations
Extent and quality of surgical resection: 59% suboptimal debunking surgery in PDS time, median operating time only 120 min.
Additional resources
Metanalysis of CORUS & EORTC55971 (Link: https://pubmed.ncbi.nlm.nih.gov/30413383)